CHMP opinion positive for Lorviqua as first-line treatment for ALK-positive advanced NSCLC.- Pfizer Inc.
The CHMP’s opinion will now be verified by the European Commission (EC) with a decision expected in the coming months. The application for the first-line use of Lorviqua was based on the results of the pivotal Phase III CROWN trial, in which Lorviqua reduced the risk of disease progression or death by 72% compared to Xalkori(crizotinib). In patients with measurable brain metastases, 82% of patients in the Lorviqua arm experienced an intracranial response (71% experiencing an intracranial complete response), compared to 23% of Xalkori patients.
Related news and insights
Scynexis, Inc. announced that the FDA has approved a second indication for Bexafemme (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC)
Eli Lilly and Company has announced that donanemab met all primary and secondary endpoints for the 6-month primary outco me analysis in the Phase III TRAILBLAZER-ALZ 4 study , providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic Alzheimer's disease treated with amyloid-targeting therapies